Hospitals and other health care providers participating in the 340B drug discount program use different approaches to tracking how much they receive in 340B savings and how those savings are used, which points to the need for greater transparency, House Energy and Commerce Committee Chairman Greg Walden, R-Ore., said at an Oversight Subcommittee hearing on the program Oct. 11.
"The lack of transparency requirements has resulted in inconsistent data and dueling reports from every side of the issue," Walden said in his prepared opening statement. "Much of the data...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?